Atossa Genetics Inc., a clinical-stage pharmaceutical company, focuses on developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions in the United States. The company is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Afimoxifene Topical Gel for the treatment and prevention of hyperplasia of the breast. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.
http://www.priceseries.com/trade/ATOS-Atossa-Genetics-Inc-stock-gains-162-percent-a-Trade-Record-by-priceSeries-2021011320210212.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments